Serum Receptor Activator of Nuclear Factor-κβ Ligand and Osteoprotegerin Levels and Ratio in Correlation with Bone Mineral Density

Fauqa Arinil Aulia, Sri Lestari Utami, Leonita Anniwati, Sony Wibisono Mudjanarko, Ferdy Royland Marpaung

Abstract


Osteoporosis is a disorder represented by manifestations of low bone mass, decreased bone tissue, and disrupted bone
microarchitecture. The diagnosis of osteoporosis so far has been based on fracture manifestations after minimal trauma or
by detecting low Bone Mineral Density (BMD). Measurement of Receptor Activator of Nuclear Factor-κβ Ligand (RANKL)
and Osteoprotegerin (OPG) levels has opened the discourse of a more specific assessment of osteoblast and osteoclast
regulation. The RANKL/OPG ratio can represent resorption and bone formation more significantly when correlated with
BMD features. This study aimed to analyze the correlation between serum RANKL and OPG levels and ratio with BMD. A total
of 58 post-menopausal females from 13 elderly in Integrated Community Health Care Surabaya and Sidoarjo were enrolled.
Data were collected by recording age, onset of menarche, onset of menopause, and Body Mass Index (BMI). Serum RANKL
and OPG levels were evaluated using sandwich ELISA from Elabscience®. The RANKL/OPG ratio was obtained from the ratio
between measured RANKL and OPG levels in serum. The proximal femur and lumbar spine BMDs were measured using
Hologic® Discovery™ QDR™ Dual-Energy X-ray Absorptiometry (DEXA). Pearson's correlation test in this study showed no
significant correlation between BMD and RANKL levels (lumbar: p=0.203; hip: p=0.283). The insignificant result was also
shown in the correlation between BMD and OPG levels (lumbar: p=0.412; hip: p=0.617). A significant result between lumbar
BMD and RANKL/OPG ratio was only found in the osteopenia subjects (p=0.001). The RANKL/OPG ratio had a significant
correlation only with osteopenia-BMD in post-menopausal females. Therefore, it could be used as supporting data in
osteoporosis screening.


Keywords


RANKL, osteoprotegerin, bone mineral density, osteoporosis, post-menopausal females

Full Text:

PDF

References


Sözen, T, Özı şı k, L, Başaran, NC. An overview and

management of osteoporosis. European Journal of

Rheumatology, 2017; 4: 46-56.

Mithal A, Kaur P. Osteoporosis in Asia: A call to action.

Curr Osteoporos Rep, 2012; 10: 245–7.

Kementerian Kesehatan Republik Indonesia. Data &

kondisi penyakit osteoporosis di Indonesia. Jakarta,

Pusat Data dan Informasi Kementerian Kesehatan

Republik Indonesia, 2015, 2-6.

Sheu A, Diamond T. Bone mineral density: Testing for

osteoporosis. Aust Prescr, 2016; 39: 35-91.

G a r n e r o P . B i o m a r k e r s f o r o s t e o p o r o s i s

management–utility in diagnosis, fracture risk

prediction, and therapy monitoring. Journal of

Endocrine Disorders, Mol Diag Ther, 2008; 12(3):

-70.

Sennels HP, Jacobsen S, Jensen T, Hansen MS,

Ostergaard M, et al. Biological variation and reference

intervals for circulating osteopontin, osteoprotegerin,

total soluble receptor activator of nuclear factor kappa

B ligand and high-sensitivity C-reactive protein. Scand

J Clin Lab Invest, 2007; 67: 821–35.

Khosla S. Mini review: The OPG/RANKL/RANK system.

Endocrinol, 2001; 142: 5050–55.

Boyce BF, Xing L. Biology of RANK, RANKL, and

osteoprotegerin. Arthritis Research & Therapy, 2007;

(S1): 1689-1697.

World Health Organization. Body mass index–BMI.

h t t p : / / w w w . e u r o . w h o . i n t / e n / h e a l t h - t o p i c s /

disease-prevention/nutrition/a-healthy-lifestyle/

body-mass-index-bmi (Updated on Nov, 2019).

World Health Organization. WHO scientific group on

the assessment of osteoporosis at primary health care

level. Brussel-Belgium, Summary Meeting Report,

; 2.

Elabscience®. Manual book-human sRANKL (soluble

receptor activator of nuclear factor-kB ligand) ELISA

th Kit, 7 Ed., USA, Elabscience®, 2017; 1-11.

E l a b s c i e n c e ® . M a n u a l b o o k - h u m a n O P G

t h (osteoprotegerin) ELISA Kit, 7 Ed., USA,

Elabscience®, 2017; 1-11.

Trofimov S, Pantsulaia I, Kobyliansky E, Livshits G.

Circulating levels of receptor activator of

nuclear factor-kB ligand/osteoprotegerin/

macrophage-colony stimulating factor in a

presumably healthy human population. European

Journal of Endocrinology, 2004; 150: 305–11.

Widodo H, Anisa FN, Lianti D. Relationship of physical

activity, diet, and age menarche with age menopause

at elderly Posyandu working area Puskesmas

Pekauman Banjarmasin. Advances in Health Science

Research, 2017; 6: 566–74.

Ahuja M. Age of menopause and determinants of

menopause age: A PAN India survey by IMS. J Mid-life

Health, 2016; 7: 126–31.

Gold EB. The timing of the age at which natural

menopause occurs. Obstet Gynecol Clin N Am, 2011;

: 425–40.

Lambrinoudaki I, Tsouvalas E, Vakaki M, Kaparos G,

Stamatelopoulos K, et al. Osteoprotegerin, soluble

receptor activator of nuclear f

Holecki M, Zahorska-Markiewicz B, Janowska J,

Nieszporek T. The influence of weight loss on

serum osteoprotegerin concentration in obese

perimenopausal women. Obesity, 2007; 15(8):

–9.

Dimitri P, Wales JK, Bishop N. Adipokines, bonederived

factors and bone turnover in obese

children; Evidence for altered fat-bone signaling

resulting in reduced bone mass. Bone, 2011;

(2): 189–96.

actor-KB ligand, and

subclinical atherosclerosis in children and

adolescents with type 1 diabetes mellitus.

International Journal of Endocrinology, 2013;

: 1-8.

Hsu YH, Venners SA, Terwedow HA, Feng Y, Niu

T, Li Z, et al. Relation of body composition, fat

mass, and serum lipids to osteoporotic fractures

and bone mineral density in Chinese men and

women. Am J Clin Nutr, 2006; 83: 146–54.

Ahmad EA, Abbas M, Amir R, Mohammad S. The

relationship between body weight, Body Mass

Index (BMI) and Bone Mineral Density (BMD) of

the lumbar spine and femoral neck in

professional cyclist of Iran and tour de France.

Iranian Journal of Health and Physical Activity,

; 4: 67–71.

Iqbal SI, Morch LS, Rosenzweig M, Dela F. The

outcome of bone mineral density measurements

on patients referred from general practise.

Journal of Clinical Densitometry, 2005; 8: 178-82.

Nabipour I, Larijani B, Vahdat K, Assadi M, Jafari

SM, et al. Relationships among serum receptor

of nuclear factor-JB ligand, osteoprotegerin,

high-sensitivity C-reactive protein, and bone

mineral density in post-menopausal women:

osteoimmunity versus osteoinflammatory. The

Journal of the North American Menopause

Society, 2009; 16(5): 950–5.

Kim SJ, Yang WG, Cho E, Park E. Relationship

between weight, body mass index, and bone

mineral density of lumbar spine in women. J

Bone Metab, 2012; 19: 95–102.

F a h r l e i t n e r - P a m m e r A , D o b n i g H ,

Piswanger-Soelkner, C. Osteoprotegerin serum

levels in women: correlation with age, bone

mass, bone turnover, and fracture status. Wien

Klin Wochenschr, 2003; 115: 291–7.

Mendez JP, Mejia DR, Pedraza J, Vazquez RMC,

Soriano R, et al. Bone mineral density in

post-menopausal Mexican-Mestizo women with

normal body mass index, overweight, or obesity.

Menopause, 2013; 20: 568–72.

Bolotin HH. DXA in-vivo BMD methodology: An

erroneous and misleading research and clinical

gauge of bone mineral status, bone fragility, and

bone remodeling. Bone, 2007; 41: 138–54.

Brown SE. Osteoporosis: Snap, crackle, and pop

some pills. Northeast Florida Med, 2006; 57: 14-20.

Shanthi JC, McLeod W, Kennedy L, McLeod K.

Osteoporosis health beliefs among younger and

older men and women. Health Educ Behav, 2008;

(5): 721–33.

Pietschmann P, Rauner M, Sipos W, Schindl

KK. Osteoporosis: An age-related and

gender-specific disease a mini-review.

Gerontology, 2009; 55: 3-12.

Liu JM, Zhao HY, Ning G, Zhao YJ, Chen Y, et al.

Relationships between the changes of serum

levels of OPG and RANKL with age, menopause,

bone biochemical markers and bone mineral

density in Chinese women aged 20-75. Calcif

Tissue Int, 2005; 76: 1–6.

Ginaldi L, Di Benedetto MC, De Martinis M.

Osteoporosis, inflammation, and aging. Immun

Ageing, 2005; 2: 14.

Gallagher JC. Advances in bone biology and new

treatments for bone loss. Maturitas, 2008; 60:

–9.




DOI: http://dx.doi.org/10.24293/ijcpml.v27i1.1627

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.